Joseph Zouein

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 14

Top Topics

Tyrosine Kinase

Epidermal Growth Factor Receptor

Small Cell Lung Cancer

Top Venues

Future oncology (London, England)

Biomarkers in medicine

Targeted oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Joseph Zouein, Elias Karam, John H Strickler, Hampig Raphael Kourie
Trastuzumab-Deruxtecan: Redefining HER2 as a Tumor Agnostic Biomarker. Targeted oncology (2024)
Joseph Zouein, Myriam Boueri, Hampig Raphael Kourie, Joseph Kattan, Elie Nemr
Advanced bladder cancer management: history in the making. Future oncology (London, England) (2023)
Joseph Zouein, Nabih Naim, Hampig Raphael Kourie
Adjuvant therapy in renal cell carcinoma in the immunotherapy era: where do we stand? Immunotherapy 15 (2) (2023)
Joseph Zouein, Nabih Naim, Hampig Raphael Kourie
Adjuvant therapy in renal cell carcinoma in the immunotherapy era: where do we stand? Immunotherapy 15 (2) (2023)
Yara Baz, Maria Rassam, Elsa Rhayem, Joseph Zouein, Joseph Gharios, Hampig Raphael Kourie
The use of dostarlimab, a safe and efficient monotherapy in MSI-H rectal cancer patients, an alternative to surgery. Immunotherapy (2023)
Hampig Raphael Kourie, Mervat Mahrous, Nabih Naim, Joseph Zouein, Zineb Benbrahim, Kakil Rasul, Mohsen Mokhtar, Ahmad Al Shehri, Mahmoud Shakeeb, Sami Khatib, Humaid Al-Shamsi, Ali Shamseddine, Elisabeth Smyth
The first Middle East and North Africa expert consensus recommendations for management of advanced gastric cancer. Future oncology (London, England) (2023)
Sasha-Jane Abi-Aad, Joseph Zouein, Antoine Chartouni, Nabih Naim, Hampig Raphael Kourie
Simultaneous inhibition of PD-1 and LAG-3: the future of immunotherapy? Immunotherapy (2023)
Joseph Zouein, Nabih Naim, Hampig Raphael Kourie
Adjuvant therapy in renal cell carcinoma in the immunotherapy era: where do we stand? Immunotherapy 15 (2) (2023)
Joseph Zouein, Nabih Naim, Hampig Raphael Kourie
Adjuvant therapy in renal cell carcinoma in the immunotherapy era: where do we stand? Immunotherapy (2023)
Samir Hachem, Yara Kassis, Maria Cr Hachem, Joseph Zouein, Joseph Gharios, Hampig R Kourie
BRCAness in biliary tract cancer: a new prognostic and predictive biomarker? Biomarkers in medicine (2023)
Hampig Raphaël Kourie, Fahad Ibnshamsah, Joseph Zouein, Nabih Naim, Salah Abbasi, Nasr Allahloubi, Manwar Al-Naqqash, Ashwaq Alolayan, Ahmed Alshehri, Nizar Bitar, Adda Bounedjar, Abdulaziz Al Farsi, Humaid El Shamsi, Ramy Ghali, Hassan Jaafar, Blaha Larbaoui, Mervat Mahrous, Hind Mrabti, Abdul Razzak Nweir, Mohamed Oukkal, Kakil Rasul, Mohsen Razavi, Rim Turfa, Sami Khatib, Ali Shamseddine
The first Middle East and North Africa expert consensus recommendations for the management of advanced colorectal cancer. Future oncology (London, England) 18 (24) (2022)
Joseph Zouein, Charbel Noujaim, Hampig Raphael Kourie
Targeting PIK3CA in HER2-positive breast cancer: what are the opportunities and the challenges? Biomarkers in medicine 15 (9) (2022)
Elissar Moujaes, Makram Khoury, Joseph Zouein, Josiane Bou Eid, Razan Mohty, Hampig Raphael Kourie
First advanced course on biomarkers in molecular and immuno-oncology in the Middle East. Future oncology (London, England) 17 (22) (2021)
Joseph Zouein, Fady Gh Haddad, Roland Eid, Hampig Raphaël Kourie
The combination of immune checkpoint inhibitors and chemotherapy in advanced non-small-cell lung cancer: the rational choice. Immunotherapy (2021)